Cyclin dependent kinase 9 inhibition is potentially a good therapeutic strategy as CDK9 is diffusely overexpressed in esophageal adenocarcinoma cells as compared to Barrett's esophagus. This evidence concerns the gene CDK9 and Barrett esophagus.